Indeed data show 'AI' is being added to job titles from trucking to teaching, signaling a fast shift toward practical AI fluency across the U.S. workforce.

Databricks signed a term sheet valuing the company at about $188 billion and is choosing another private raise over an immediate IPO. The capital will fuel enterprise AI products and give management more runway to time a public listing.

Beijing startup Moonshot unveiled Kimi K3 — a 2.8T open‑weight AI model — at WAIC, rattling markets and forcing Silicon Valley to reassess the frontier.

A Bay Area resident sued Apple in federal court, saying the company misled users about Hide My Email after researchers found a flaw that can expose real addresses.

Massive AI spending plans and a TSMC expansion rattled chip stocks Friday, sending markets lower. Bay Area tech names and suppliers led the decline.

ECL has ordered PowerCell PS190 units and signed an MoU for about 300 MW, starting at its 35MW CSC‑1 campus in Santa Clara and building on a Mountain View pilot.

Santa Clara's Autonomous Healthcare won FDA De Novo authorization for Syncron‑E, the first ventilator waveform analysis device, clearing a path for AI‑assisted ICU monitoring.

JPMorgan CEO Jamie Dimon warned that Anthropic’s Mythos AI poses urgent cybersecurity risks and needs tight controls as regulators weigh permissioned access.

Brussels ordered Google to open Android and share anonymized search signals with rival AI firms, setting firm deadlines and raising privacy and legal questions. The move could reshape how assistants and search compete worldwide.

Greylock raised $1.5B for early‑stage AI startups while pledging a concentrated, hands‑on approach for founders in the Bay Area.

A Common Sense Media safety assessment says Google Search’s built‑in AI can mislead children and schools and parents lack an easy way to turn the feature off. Here’s what testers found and what to do next.

Anthro Energy's Proteus electrolyte could make batteries safer and denser. The Alameda startup has DOE and CEC backing as it prepares to scale.

BioMarin said the FDA accepted a supplemental filing to convert VOXZOGO from accelerated to full approval for children with achondroplasia; PDUFA date is Feb. 28, 2027.